EGFR is a key link in GBM's sensitivity to dopamine-like inhibitors

Glioblastoma (GBM) is a common primary malignant brain tumor with a survival of no more than 2 years.
studies have shown that receptor tyrosine kinase (RTK) and epidermal growth factor receptors (epidermal growth factor receptors, EGFR) often amplification or mutation in GBM;
Yuyu He of the University of Minnesota, USA, and others analyzed the expression patterns of DRD2 and EGFR using the Cancer Genome Atlas (TCGA) GBM database and related literature;
study Methods Numerous studies have supported the use of DRD2 inhibitors in the treatment of GBM, but not all GBM patients are effective.
, the relevant molecular factors are essential for protein translation.
study showed that DRD2 was negatively related to the expression of EGFR in GBM.
DRD2 is a 7 transfilm G protein conjunctivity, its role is mainly manifested in the transmission of nerve function, DRD2 overextending will induce GBM to occur.
first analyzed the expression patterns of DRD2 and EGFR in clinical GBM specimens using TCGA data, as well as mRNA expression patterns independent of non-TCGA.
in two groups of data, high expressions of DRD2 and EGFR were observed clinically in 25% of GBM samples.
clinical GBM samples, DRD2 was negatively associated with EGFR expression.
proteins associated with drAD2 and other RTK pathflytes, such as plateboard growth factors α and β, were negatively associated, independent of GBM incidence.
note that DRD2 was associated with EGFR in two separate patient groups, but this correlation was imperfect.
in two sets of expression data, EGFR high expression has a good correlation with classical subtypes.
DRD2 expression pattern is comparable between different subtypes.
results of these studies, subsequent experimental results confirm that the negative correlation between DRD2 and EGFR expression may be related to the overlap of path effects, i.e. the activation of one path can inhibit another path.
different EGFR expressions, such as high expression of EGFR, and EGFR low expression of glioma PDX cell line sensitivity to independent DRD2 inhibitors.
highly expressed GBM cell line with EGFR is insensitive to fluorosterol and ONC201, two DRD2 inhibitors.
, EGFR's low-expression GBM cell line is highly sensitive to fluorosterol or ONC201.
Based on the above results, the researchers concluded that EGFR low-expression GBM patients were sensitive to fluoroquinol or ONC201, including three aspects: (1) EGFR and DRD2 expression in GBM were negatively correated;
: The intellectual property rights of the contents of the information published by the Brain Medical Exchange, the Information of God and the Consulting Institute of Brain Medicine are owned by the organizers, the original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be licensed for use, the source must also be indicated.
welcome to forward and share.